Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy

International Journal for Vitamin and Nutrition Research

Volumn 83, Issue 2, 2013, Pages 77-85

  Noori, Nazanin ^a   Tabibi, Hadi ^b   Hosseinpanah, Farhad ^b   Hedayati, Mehdi ^b   Nafar, Mohsen ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Advanced glycation end products; Blood pressure; Diabetic nephropathy; Lipoic acid; Oxidative stress; Pyridoxine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; CREATININE; ENDOTHELIN 1; GLUCOSE; MALONALDEHYDE; NITRIC OXIDE; PENTOSIDINE; PLACEBO; PYRIDOXINE; THIOCTIC ACID;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVENING DOSAGE; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; MICROALBUMINURIA; MIDDLE AGED; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADVANCED GLYCATION END-PRODUCTS; BLOOD PRESSURE; DIABETIC NEPHROPATHY; LIPOIC ACID; OXIDATIVE STRESS; PYRIDOXINE;

ADULT; AGED; ALBUMINURIA; ARGININE; BLOOD PRESSURE; CREATININE; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; PYRIDOXINE; THIOCTIC ACID;

EID: 84894380843     PISSN: 03009831     EISSN: 16642821     Source Type: Journal    
DOI: 10.1024/0300-9831/a000147     Document Type: Article

References (35)

1. International Diabetes Federation, International Society of Nephrology. (2003) Diabetes and Kidney Disease: Time to Act. International Diabetes Federation, Brussels.
2. Ruggenenti, P. and Remuzzi, G. (2000) Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol. Dial. Transplant. 15, 1900-1902.
3. Gross, J.L., Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L. and Zelmanovitz, T. (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28, 164-176.
4. Schena, F.P. and Gesualdo, L. (2005) Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 30-33.
5. Heidland, A., Sebekova, K. and Schinzel, R. (2001) Advanced glycation end products and the progressive course of renal disease. Am. J. Kidney Dis. 38, S100-S106.
6. Forbes, J.M., Cooper, M.E., Oldfield, M.D. and Thomas, M.C. (2003) Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14, S254-S258.
7. Yamagishi, S.I. and Imaizumi, T. (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11, 2279-2299.
8. Wilmer, W.A., Rovin, B.H., Hebert, C.J., Rao, S.V., Kumo, K. and Hebert, L.A. (2003) Management of glomerular proteinuria: a commentary. J. Am. Soc. Nephrol. 14, 3217-3232.
9. Nakamura, S., Li, H., Adijiang, A., Pischetsrieder, M. and Niwa, T. (2007) Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol. Dial. Transplant. 22, 2165-2174.
10. Degenhardt, T.P., Alderson, N.L., Arrington, D.D., Beattie, R.J., Basgen, J.M., Steffes, M.W. et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61, 939-950.
11. Packer, L., Kraemer, K. and Rimbach, G. (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17, 888-895.
12. Melhem, M.F., Craven, P.A. and Derubertis, F.R. (2001) Effects of dietary supplementation of a-lipoic acid on early glomerular injury in diabetes mellitus. J. Am. Soc. Nephrol. 12, 124-133.
13. Melhem, M.F., Craven, P.A., Liachenko, J. and De- Rubertis, F.R. (2002) a-Lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J. Am. Soc. Nephrol. 13, 108-116.
14. Williams, M.E., Bolton, W.K., Khalifah, R.G., Degenhardt, T.P., Schotzinger, R.J. and McGill, J.B. (2007) Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27, 605-614.
15. Morcos, M., Borcea, V., Isermann, B., Gehrke, S., Ehret, T., Henkels, M. and et al. (2001) Effect of a-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diab. Res. Clin. Pract. 52, 175-183.
16. Winiarska, K., Malinska, D., Szymanski, K., Dudziak, M. and Bryla, J. (2008) Lipoic acid ameliorates oxidative stress and renal injury in alloxan diabetic rabbits. Biochimie 90, 450-459.
17. Mason, R.M. and Wahab, N.A. (2003) Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 14,1358-1373.
18. Shah, S.V., Baliga, R., Rajapurkar, M. and Fonseca, V.A. (2007) Oxidants in chronic kidney disease. J. Am. Soc. Nephrol. 18, 16-28.
19. Bohlender, J.M., Franke, S., Stein, G. and Wolf, G. (2005) Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 289, F645-F659.
20. Uribarri, J. and Tuttle, K.R. (2006) Advanced glycation end products and nephrotoxicity of high-protein diets. Clin. J. Am. Soc. Nephrol. 1, 1293-1299.
21. Kanwar, Y.S., Wada, J., Sun, L., Xie, P., Wallner, E.I., Chen, S. et al. (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp. Bio. Med. 233, 4-11.
22. Zhou, X.J., Vaziri, N.D., Zhang, J., Wang, H.W. and Wang, X.Q. (2002) Association of renal injury with nitric oxide deficiency in aged SHR: Prevention by hypertension control with AT1 blockade. Kidney Int. 62, 914-921.
23. Voziyan, P.A., Khalifah, R.G., Thibaudeau, C., Yildiz, A., Jacob, J., Serianni, A.S. et al. (2003) Modification of proteins in vitro by physiological levels of glucose. J. Biol. Chem. 278, 46616-46624.
24. Miyata, T., Kurokawa, K. and Van Ypersele De Strihou, C. (2000) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J. Am. Soc. Nephrol. 11, 1744-1752.
25. Thirunavukkarasu, V., Anitha Nandhini, A.T. and Anuradha, C.V. (2005) Lipoic acid improves glucose utilisation and prevents protein glycation and AGE formation. Pharmazie 60, 772-775.
26. Lee, H.B., Yu, M.R., Yang, Y., Jiang, Z. and Ha, H. (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 14, S241-S245.
27. Mohamed, A.K., Bierhaus, A., Schiekofer, S., Tritschler, H., Ziegler, R. and Nawroth, P.P. (1999) The role of oxidative stress and NF-?B activation in late diabetic complications. BioFactors 10, 157-167.
28. Borcea, V., Nourooz-Zadeh, J., Wolff, S.P., Klevesath, M., Hofmann, M., Urich, H. et al. (1999) alpha- Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic. Biol. Med. 26, 1495-500.
29. Obrosova, I.G., Fathallah, L., Liu, E. and Nourooz- Zadeh, J. (2003) Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Free Radic. Biol. Med. 34, 186-195.
30. Maritim, A.C., Sanders, R.A. and Watkins, J.B., 3rd. (2003) Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats. J. Nutr. Biochem. 14, 288-294.
31. Muellenbach, E.A., Diehl, C.J., Teachey, M.K., Lindborg, K.A., Archuleta, T.L., Harrell, N.B. et al. (2008) Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alphalipoic acid on insulin resistance in the obese Zucker rat. Metabolism 57, 1465-1472.
32. Jacob, S., Ruus, P., Hermann, R., Tritschler, H.J., Maerker, E., Renn, W. et al. (1999) Oral administration of RAC-a-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo- controlled pilot trial. Free Radic. Biol. Med. 27, 309-314.
33. Evans, J.L., Heymann, C.J., Goldfine, I.D. and Gavin, L.A. (2002) Pharmacokinetics, tolerability, and fructosamine- lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr. Pract. 8, 29-35.
34. Kamenova, P. (2006) Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens) 5, 251-258.
35. Thirunavukkarasu, V., Anitha Nandhini, A.T. and Anuradha, C.V. (2004) Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats. J. Comp. Physiol. B. 174, 587-592.